Smith W T, Glaudin V
Pacific Northwest Clinical Research Center, Portland, OR 97232.
J Clin Psychiatry. 1992 Feb;53 Suppl:36-9.
Paroxetine is a phenylpiperidine compound that selectively inhibits neuronal serotonin uptake in man. In this study, the efficacy of paroxetine was compared with that of placebo in the treatment of 66 outpatients with the diagnosis of moderate-to-severe major depression. The research was a 6-week, prospective, double-blind design after a 1-week placebo baseline phase. Paroxetine was associated with a consistent pattern of greater improvement on the primary efficacy scales, but the differences were not statistically significant. Paroxetine did produce significantly greater improvement than placebo for patients whose illness had lasted more than 1 year, and there was a significant reduction in suicidal ideation. Significantly fewer dropouts were due to lack of efficacy in those patients treated with paroxetine compared with those in the placebo group. Paroxetine was well tolerated. There was no difference between paroxetine and placebo in the rate of adverse effects or in the number of patients who dropped out because of adverse effects.
帕罗西汀是一种苯基哌啶化合物，可选择性抑制人体神经元对血清素的摄取。在本研究中，将帕罗西汀与安慰剂治疗66例诊断为中度至重度重度抑郁症的门诊患者的疗效进行了比较。该研究为为期6周的前瞻性双盲设计，此前有1周的安慰剂基线期。帕罗西汀在主要疗效量表上的改善情况始终更好，但差异无统计学意义。对于病程超过1年的患者，帕罗西汀的改善明显优于安慰剂，且自杀意念显著减少。与安慰剂组相比，接受帕罗西汀治疗的患者因疗效不佳而退出的人数明显更少。帕罗西汀耐受性良好。帕罗西汀与安慰剂在不良反应发生率或因不良反应而退出的患者数量方面没有差异。
